TNGX
insider transactionsTango Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-27.0K
0 buy · 27.0K sell
Net value · 30d
-$617.6K
$0 in · $617.6K out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
2
0 buy · 27.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
25.0K sh
Own New
-
Grant·A
Director
$0
4.0K sh
Own +11%
-
Grant·A
Director
$0
3.6K sh
Own New
-
Grant·A
Director
$0
570 sh
Own +3%
-
Grant·A
Director
$0
25.0K sh
Own New
-
Grant·A
Director
$0
4.0K sh
Own +19%
-
Grant·A
Director
$0
25.0K sh
Own New
-
Grant·A
Director
$0
4.0K sh
Own +32%
-
Exercise·M
Crystal Adam KEY
President, R&D · 10b5-1
$0
27.0K sh
Own +9%
-
Sell·S
Crystal Adam KEY
President, R&D · 10b5-1
$480.9K
20.9K sh · $23.06
Own -15%
-
Sell·S
Crystal Adam KEY
President, R&D · 10b5-1
$136.6K
6.1K sh · $22.25
Own -4%
-
Exercise·M
Crystal Adam KEY
President, R&D · 10b5-1
$140.4K
27.0K sh · $5.20
Own +23%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 5, 2026 | Rothenberg Mace | Grant A | 25.0K | $0 |
| Jun 5, 2026 | Rothenberg Mace | Grant A | 4.0K | $0 |
| Jun 5, 2026 | Lee Sung | Grant A | 3.6K | $0 |
| Jun 5, 2026 | Lee Sung | Grant A | 570 | $0 |
| Jun 5, 2026 | Ketchum John B | Grant A | 25.0K | $0 |
| Jun 5, 2026 | Ketchum John B | Grant A | 4.0K | $0 |
| Jun 5, 2026 | Calhoun Lesley Ann | Grant A | 25.0K | $0 |
| Jun 5, 2026 | Calhoun Lesley Ann | Grant A | 4.0K | $0 |
| Jun 1, 2026 | Crystal Adam KEY 10b5-1 | Exercise M | 27.0K | $0 |
| Jun 1, 2026 | Crystal Adam KEY 10b5-1 | Sell S | 20.9K | $480.9K |
| Jun 1, 2026 | Crystal Adam KEY 10b5-1 | Sell S | 6.1K | $136.6K |
| Jun 1, 2026 | Crystal Adam KEY 10b5-1 | Exercise M | 27.0K | $140.4K |
About TNGX insider trading
This page tracks insider transactions for Tango Therapeutics, Inc. (TNGX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.